2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events A 2024 Meta-analysis of 13 multiple cardiovascular outcome trials has documented that GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)
If you choose to drink occasionally, be aware that your tolerance has likely changed and adjust consumption accordingly
Bramax for Poor Skin Texture 500Mg 90Capsules Multivitamin with Vitamins, Minerals Blends - Antioxidants, Immunity, Brain Health Pre & Probiotics Supplement for Men and Women, with 30 Billion CFU Prebiotics, Improves
Regular in-person or in-home follow-up visits with full biometric reassessment